vs
Side-by-side financial comparison of Ingersoll Rand (IR) and KINROSS GOLD CORP (KGC). Click either name above to swap in a different company.
KINROSS GOLD CORP is the larger business by last-quarter revenue ($2.5B vs $2.1B, roughly 1.2× Ingersoll Rand).
Ingersoll Rand Inc. is an American multinational company that provides flow creation and industrial products. The company was formed in February 2020 through the spinoff of the industrial segment of Ingersoll-Rand plc and its merger with Gardner Denver. Its products are sold under more than 40 brands across all major global markets.
Kinross Gold Corporation is a Canadian-based gold and silver mining company founded in 1993 and headquartered in Toronto, Ontario, Canada. Kinross currently operates six active gold mines, and was ranked fifth of the "10 Top Gold-mining Companies" of 2019 by InvestingNews. The company's mines are located in Brazil, Mauritania, and the United States. It trades under the KGC ticker in the New York Stock Exchange, and under K in the Toronto Stock Exchange.
IR vs KGC — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2023
| Metric | | |
|---|---|---|
| Revenue | $2.1B | $2.5B |
| Net Profit | $266.1M | — |
| Gross Margin | 42.6% | 7.3% |
| Operating Margin | 18.7% | — |
| Net Margin | 12.7% | — |
| Revenue YoY | 10.1% | — |
| Net Profit YoY | 15.8% | — |
| EPS (diluted) | $0.67 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.9B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $1.8B | — | ||
| Q1 24 | $1.7B | — |
| Q4 25 | $266.1M | — | ||
| Q3 25 | $244.1M | — | ||
| Q2 25 | $-115.3M | — | ||
| Q1 25 | $186.5M | — | ||
| Q4 24 | $229.8M | — | ||
| Q3 24 | $221.6M | — | ||
| Q2 24 | $185.0M | — | ||
| Q1 24 | $202.2M | — |
| Q4 25 | 42.6% | — | ||
| Q3 25 | 43.7% | — | ||
| Q2 25 | 43.7% | — | ||
| Q1 25 | 44.6% | — | ||
| Q4 24 | 42.9% | — | ||
| Q3 24 | 43.8% | — | ||
| Q2 24 | 43.9% | — | ||
| Q1 24 | 44.7% | — |
| Q4 25 | 18.7% | — | ||
| Q3 25 | 19.2% | — | ||
| Q2 25 | 4.0% | — | ||
| Q1 25 | 17.6% | — | ||
| Q4 24 | 20.0% | — | ||
| Q3 24 | 19.1% | — | ||
| Q2 24 | 15.1% | — | ||
| Q1 24 | 17.6% | — |
| Q4 25 | 12.7% | — | ||
| Q3 25 | 12.5% | — | ||
| Q2 25 | -6.1% | — | ||
| Q1 25 | 10.9% | — | ||
| Q4 24 | 12.1% | — | ||
| Q3 24 | 11.9% | — | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | 12.1% | — |
| Q4 25 | $0.67 | — | ||
| Q3 25 | $0.61 | — | ||
| Q2 25 | $-0.29 | — | ||
| Q1 25 | $0.46 | — | ||
| Q4 24 | $0.57 | — | ||
| Q3 24 | $0.54 | — | ||
| Q2 24 | $0.45 | — | ||
| Q1 24 | $0.50 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.2B | $418.1M |
| Total DebtLower is stronger | $4.8B | $751.5M |
| Stockholders' EquityBook value | $10.1B | — |
| Total Assets | $18.3B | $10.4B |
| Debt / EquityLower = less leverage | 0.47× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.5B | — |
| Q4 25 | $4.8B | — | ||
| Q3 25 | $4.8B | — | ||
| Q2 25 | $4.8B | — | ||
| Q1 25 | $4.8B | — | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $4.8B | — | ||
| Q2 24 | $4.8B | — | ||
| Q1 24 | $2.7B | — |
| Q4 25 | $10.1B | — | ||
| Q3 25 | $10.1B | — | ||
| Q2 25 | $10.1B | — | ||
| Q1 25 | $10.5B | — | ||
| Q4 24 | $10.2B | — | ||
| Q3 24 | $10.3B | — | ||
| Q2 24 | $10.0B | — | ||
| Q1 24 | $9.9B | — |
| Q4 25 | $18.3B | — | ||
| Q3 25 | $18.2B | — | ||
| Q2 25 | $18.1B | — | ||
| Q1 25 | $18.4B | — | ||
| Q4 24 | $18.0B | — | ||
| Q3 24 | $18.2B | — | ||
| Q2 24 | $17.8B | — | ||
| Q1 24 | $15.5B | — |
| Q4 25 | 0.47× | — | ||
| Q3 25 | 0.47× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.48× | — | ||
| Q1 24 | 0.27× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $499.0M | $649.0M |
| Free Cash FlowOCF − Capex | $461.5M | — |
| FCF MarginFCF / Revenue | 22.1% | — |
| Capex IntensityCapex / Revenue | 1.8% | — |
| Cash ConversionOCF / Net Profit | 1.88× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.2B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $499.0M | — | ||
| Q3 25 | $354.6M | — | ||
| Q2 25 | $245.7M | — | ||
| Q1 25 | $256.4M | — | ||
| Q4 24 | $526.2M | — | ||
| Q3 24 | $404.0M | — | ||
| Q2 24 | $304.9M | — | ||
| Q1 24 | $161.6M | — |
| Q4 25 | $461.5M | — | ||
| Q3 25 | $325.5M | — | ||
| Q2 25 | $210.4M | — | ||
| Q1 25 | $222.7M | — | ||
| Q4 24 | $490.9M | — | ||
| Q3 24 | $374.3M | — | ||
| Q2 24 | $283.1M | — | ||
| Q1 24 | $99.3M | — |
| Q4 25 | 22.1% | — | ||
| Q3 25 | 16.6% | — | ||
| Q2 25 | 11.1% | — | ||
| Q1 25 | 13.0% | — | ||
| Q4 24 | 25.9% | — | ||
| Q3 24 | 20.1% | — | ||
| Q2 24 | 15.7% | — | ||
| Q1 24 | 5.9% | — |
| Q4 25 | 1.8% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.6% | — | ||
| Q2 24 | 1.2% | — | ||
| Q1 24 | 3.7% | — |
| Q4 25 | 1.88× | — | ||
| Q3 25 | 1.45× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.37× | — | ||
| Q4 24 | 2.29× | — | ||
| Q3 24 | 1.82× | — | ||
| Q2 24 | 1.65× | — | ||
| Q1 24 | 0.80× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IR
| Transferred At Point In Time | $1.5B | 71% |
| Transferred Over Time | $193.0M | 9% |
| Precision And Science Technologies Segment | $183.1M | 9% |
| Acquisitions In2024 | $175.6M | 8% |
| Acquisitions In2025 | $70.8M | 3% |
KGC
Segment breakdown not available.
